[go: up one dir, main page]

PE20140234A1 - Compuestos de 2-amino-4-ariltiazol como antagonistas de trpa1 - Google Patents

Compuestos de 2-amino-4-ariltiazol como antagonistas de trpa1

Info

Publication number
PE20140234A1
PE20140234A1 PE2013001454A PE2013001454A PE20140234A1 PE 20140234 A1 PE20140234 A1 PE 20140234A1 PE 2013001454 A PE2013001454 A PE 2013001454A PE 2013001454 A PE2013001454 A PE 2013001454A PE 20140234 A1 PE20140234 A1 PE 20140234A1
Authority
PE
Peru
Prior art keywords
compounds
alkyl
aryltiazole
amino
tetrahydrotieno
Prior art date
Application number
PE2013001454A
Other languages
English (en)
Inventor
Sukeerthi Kumar
Abraham Thomas
Sachin Sundarlal Chaudhari
Bipin Parsottam Kansagra
Venkata Ramana Yemireddy
Neelima Khairatkar-Joshi
Indranil Mukhopadhyay
Girish Gudi
Original Assignee
Glenmark Phamaceuticals S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46235162&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20140234(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glenmark Phamaceuticals S A filed Critical Glenmark Phamaceuticals S A
Publication of PE20140234A1 publication Critical patent/PE20140234A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE 2-AMINO-4-ARILTIAZOL DE FORMULA (I) DONDE Het ES UN COMPUESTO DE FORMULA (a), (b), ENTRE OTROS, EN DONDE Ra, Rb Y Rd SON CADA UNO H O ALQUILO(C1-C4); R1 ES H; P ES (i), (ii), ENTRE OTROS, EN DONDE R3 ES ALQUILO(C1-C8) O UN ANILLO HETEROCICLICO DE 3 A 15 MIEMBROS; R8 ES H, ALQUILO(C1-C4), ENTRE OTROS; R2 ES HALOGENO, HALOALQUILO(C1-C8) O HALOALCOXI(C1-C8); m ES DE 0 A 5. SON COMPUESTOS PREFERIDOS: DIHIDROGENO FOSFATO DE [2-{[(1,3-DIMETIL-2,4-DIOXO-1,2,3,4-TETRAHIDROTIENO[2,3-d]PIRIMIDIN-5-IL)ACETIL]IMINO}-4-[3-FLUORO-4-(TRIFLUOROMETIL)FENIL]-1,3-TIAZOL-3(2H)-IL]METILO; DIHIDROGENO FOSFATO DE [4-[2,4-DIFLUORO-3-(TRIFLUOROMETIL)FENIL]-2-{[(1,3-DIMETIL-2,4-DIOXO-1,2,3,4-TETRAHIDROTIENO[2,3-d]PIRIMIDIN-5-IL)ACETIL]IMINO}-1,3-TIAZOL-3(2H)-IL]METILO; ENTRE OTROS. TAMBIEN SE REFIERE UN PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON ANTAGONISTAS DEL RECEPTOR DE POTENCIAL TRANSITORIO DE ANQUIRINA TIPO 1 (TRPA1) SIENDO UTILES EN EL TRATAMIENTO DEL DOLOR CRONICO, DOLOR NEUROPATICO, DOLOR OSTEOARTRITICO
PE2013001454A 2010-12-20 2011-12-15 Compuestos de 2-amino-4-ariltiazol como antagonistas de trpa1 PE20140234A1 (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
IN3451MU2010 2010-12-20
US201061428327P 2010-12-30 2010-12-30
IN748MU2011 2011-03-16
US201161466535P 2011-03-23 2011-03-23
IN1569MU2011 2011-05-25
US201161495002P 2011-06-09 2011-06-09
IN2741MU2011 2011-09-28
US201161552076P 2011-10-27 2011-10-27

Publications (1)

Publication Number Publication Date
PE20140234A1 true PE20140234A1 (es) 2014-03-08

Family

ID=46235162

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013001454A PE20140234A1 (es) 2010-12-20 2011-12-15 Compuestos de 2-amino-4-ariltiazol como antagonistas de trpa1

Country Status (20)

Country Link
US (3) US8592398B2 (es)
EP (1) EP2655377B1 (es)
JP (1) JP5694560B2 (es)
KR (1) KR101591153B1 (es)
CN (1) CN103261201B (es)
AP (1) AP3391A (es)
AR (1) AR084294A1 (es)
AU (1) AU2011346763B2 (es)
BR (1) BR112013014692A2 (es)
CA (1) CA2820448A1 (es)
CL (1) CL2013001810A1 (es)
EA (1) EA023141B1 (es)
MX (1) MX336549B (es)
MY (1) MY159059A (es)
PE (1) PE20140234A1 (es)
PH (1) PH12013501290A1 (es)
SG (1) SG191173A1 (es)
TW (1) TWI515199B (es)
UA (1) UA109916C2 (es)
WO (1) WO2012085662A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101734955B1 (ko) 2008-11-07 2017-05-12 메사추세츠 인스티튜트 오브 테크놀로지 아미노알콜 리피도이드 및 그의 용도
EA023141B1 (ru) 2010-12-20 2016-04-29 Гленмарк Фармасьютикалс С.А. Соединения 2-амино-4-арилтиазола в качестве антагонистов trpa1
EP2691443B1 (en) 2011-03-28 2021-02-17 Massachusetts Institute of Technology Conjugated lipomers and uses thereof
EP2742048B1 (en) 2011-08-09 2016-04-27 Hydra Biosciences, Inc. Inhibiting transient receptor potential ion channel trpa1
MX363734B (es) 2011-10-27 2019-03-29 Massachusetts Inst Technology Derivados de aminoacidos funcionalizados en la terminal n capaces de formar microesferas encapsuladoras de farmaco.
CN104203236A (zh) 2012-01-17 2014-12-10 味之素株式会社 杂环酰胺衍生物和含有其的药物
JP5989900B2 (ja) 2012-06-08 2016-09-07 グレンマーク ファーマシューティカルズ， エセ．アー． ２−アミノ−４−アリールチアゾール化合物のアミド及びその塩類
PT2903965T (pt) 2012-10-01 2017-06-06 Orion Corp Derivados de n-prop-2-inilcarboxamida e sua utilização como antagonistas de trpa1
US9394308B2 (en) 2013-01-18 2016-07-19 Merck Sharp & Dohme Corp. Inhibiting the transient receptor potential A1 ion channel
GB201309333D0 (en) * 2013-05-23 2013-07-10 Agency Science Tech & Res Purine diones as WNT pathway modulators
US9198898B2 (en) 2013-06-24 2015-12-01 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
US8906951B1 (en) 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
CA2926389A1 (en) 2013-10-15 2015-04-23 Glenmark Pharmaceuticals S.A. Pharmaceutical composition comprising a trpa1 antagonist and an analgesic agent
WO2015127186A1 (en) * 2014-02-24 2015-08-27 The Johns Hopkins University Tmem100 peptides and variants thereof and their use in treating or preventing diseases or conditions
WO2016205691A1 (en) 2015-06-19 2016-12-22 Massachusetts Institute Of Technology Alkenyl substituted 2,5-piperazinediones and their use in compositions for delivering an agent to a subject or cell
FR3037956B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2017060488A1 (en) 2015-10-09 2017-04-13 Almirall, S.A. New trpa1 antagonists
WO2017064068A1 (en) 2015-10-14 2017-04-20 Almirall, S.A. New trpa1 antagonists
CN108727400B (zh) * 2017-05-24 2021-07-09 四川晶华生物科技有限公司 一种治疗肿瘤的化合物
US10710994B2 (en) 2018-03-19 2020-07-14 Genentech, Inc. Oxadiazole transient receptor potential channel inhibitors
CN120285204A (zh) * 2018-10-23 2025-07-11 G·E·霍格 用于治疗肺的组合物和方法
CN114945408B (zh) 2019-10-15 2024-04-16 勃林格殷格翰国际有限公司 作为trpa1抑制剂的噻吩并嘧啶酮
CA3153618A1 (en) * 2019-10-15 2021-04-22 Boehringer Ingelheim International Gmbh Thienopyrimidones as trpa1 inhibitors
WO2021216749A1 (en) * 2020-04-22 2021-10-28 George Edward Hoag Method for treating viral and bacterial infection through inhalation therapy
CN111437275B (zh) * 2020-05-14 2021-03-19 黑龙江中医药大学 一种用于外科手术后抗炎和镇痛的药物及其应用
US12180223B2 (en) 2021-04-14 2024-12-31 Boehringer Ingelheim International Gmbh 3H,4H-thieno[2,3-d]pyrimidin-4-one derivatives as TRPA1 inhibitors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2518916A1 (en) 2003-04-03 2004-10-21 Joseph R. Garlich Pi-3 kinase inhibitor prodrugs
TW200720264A (en) * 2005-04-25 2007-06-01 Lundbeck & Co As H Pro-drugs of n-thiazol-2-yl-benzamide derivatives
TWI610684B (zh) 2005-12-22 2018-01-11 海卓勒生物科學公司 用於調節ｔｒｐａ１功能之化合物
DK2170309T3 (en) * 2007-06-22 2017-01-09 Hydra Biosciences Inc Dioxo-2,6, -2,3-dihydro-1H-purine compounds useful in the treatment of diseases related to activity of TRPA1 channel
WO2009118596A2 (en) 2008-03-26 2009-10-01 Glenmark Pharmaceuticals, S. A. Phthalimide derivatives as trpa1 modulators
WO2009144548A1 (en) 2008-05-28 2009-12-03 Glenmark Pharmaceuticals S.A. Imidazo [2,1-b] purine derivatives as trpa1 modulators
WO2010004390A1 (en) 2008-06-17 2010-01-14 Glenmark Pharmaceuticals, S.A. Quinazoline dione derivatives as trpa1 modulators
WO2009158719A2 (en) 2008-06-27 2009-12-30 Hydra Biosciences, Inc. Methods and compositions for treating disorders
TW201026700A (en) 2008-12-22 2010-07-16 Hydra Biosciences Inc Compositions useful for treating disorders related to TRPA1
US8623880B2 (en) * 2009-03-23 2014-01-07 Glenmark Pharmaceuticals S.A. Fused pyrimidine-dione derivatives as TRPA1 modulators
PT2411397E (pt) 2009-03-23 2013-06-06 Glenmark Pharmaceuticals Sa Derivados de isotiazolo-pirimidinadiona como moduladores de trpa1
CN102361874A (zh) 2009-03-23 2012-02-22 格兰马克药品股份有限公司 作为trpa1调节剂的呋喃并嘧啶二酮衍生物
MX2011009824A (es) 2009-03-23 2012-01-25 Glenmark Pharmaceuticals Sa Derivados de pirimidina-diona fusionados como moduladores del trpa1.
WO2010125469A1 (en) 2009-04-29 2010-11-04 Glenmark Pharmaceuticals, S.A. Pyrimidinedione-fused heterocyclic compounds as trpa1 modulators
WO2010132838A1 (en) 2009-05-14 2010-11-18 Hydra Biosciences, Inc. Compounds useful for treating disorders related to trpa1
WO2011114184A1 (en) 2010-03-15 2011-09-22 Glenmark Pharmaceuticals S.A. Amides of heterocyclic compounds as trpa1 inhibitors
WO2011132017A1 (en) 2010-04-19 2011-10-27 Glenmark Pharmaceuticals S.A. Pyrido[3,4-d]pyrimidinyl acetamide derivatives as trpa1 modulators
EA023141B1 (ru) 2010-12-20 2016-04-29 Гленмарк Фармасьютикалс С.А. Соединения 2-амино-4-арилтиазола в качестве антагонистов trpa1

Also Published As

Publication number Publication date
TW201300402A (zh) 2013-01-01
JP5694560B2 (ja) 2015-04-01
US9073955B2 (en) 2015-07-07
AU2011346763A1 (en) 2013-06-06
HK1191008A1 (zh) 2014-07-18
JP2014501755A (ja) 2014-01-23
US8889862B2 (en) 2014-11-18
EA201390947A1 (ru) 2014-07-30
KR101591153B1 (ko) 2016-02-02
EP2655377B1 (en) 2016-03-30
KR20130102099A (ko) 2013-09-16
CN103261201B (zh) 2015-04-22
AP3391A (en) 2015-08-31
CA2820448A1 (en) 2012-06-28
SG191173A1 (en) 2013-07-31
MX336549B (es) 2016-01-22
US20140045865A1 (en) 2014-02-13
TWI515199B (zh) 2016-01-01
WO2012085662A1 (en) 2012-06-28
UA109916C2 (uk) 2015-10-26
US20140051667A1 (en) 2014-02-20
PH12013501290A1 (en) 2013-08-12
AP2013006906A0 (en) 2013-06-30
BR112013014692A2 (pt) 2016-11-29
AU2011346763A2 (en) 2013-06-27
CL2013001810A1 (es) 2014-01-24
CN103261201A (zh) 2013-08-21
EP2655377A1 (en) 2013-10-30
MY159059A (en) 2016-12-15
US20120157411A1 (en) 2012-06-21
EA023141B1 (ru) 2016-04-29
US8592398B2 (en) 2013-11-26
AU2011346763B2 (en) 2016-01-07
AR084294A1 (es) 2013-05-08
MX2013006634A (es) 2013-12-16

Similar Documents

Publication Publication Date Title
PE20140234A1 (es) Compuestos de 2-amino-4-ariltiazol como antagonistas de trpa1
PE20091818A1 (es) DERIVADOS POLISUSTITUIDOS DE 2-ARIL-6-FENIL-IMIDAZO[1,2-a] PIRIDINAS, SU PREPARACION Y SU APLICACION EN TERAPEUTICA
PE20090596A1 (es) Imidazoles biciclicos fusionados
PE20191245A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
PE20091492A1 (es) Compuestos y composiciones como inhibidores de c-kit y de la cinasa pdgfr
PE20141974A1 (es) Compuestos de heterociclilo
PE20121815A1 (es) Compuestos de pirrolo-pirimidina como inhibidores de cdk4/6
PE20141674A1 (es) Derivados de heterociclos biciclicos para el tratamiento de la hipertension arterial pulmonar
PE20141281A1 (es) Compuestos de tetrahidropirido-piridina y tetrahidropirido-pirimidina y su uso como moduladores de receptores de c5a
PE20090904A1 (es) ARILOXAZOLES SUSTITUIDOS COMO LIGANDOS DE LOS RECEPTORES DE ADENOSINA A1 Y/O A2b
PE20120534A1 (es) PIRIMIDINAS FUSIONADAS COMO INHIBIDORES DE Akt
PE20150218A1 (es) Nuevos derivados fosfatos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
PE20130386A1 (es) Derivados de indolizina, su procedimiento de preparacion y su aplicacion en terapeutica
PE20081612A1 (es) Analogos de las pterinas
PE20090674A1 (es) Compuestos multiciclicos
AR083058A1 (es) Compuestos de estructura de imidazotriazinona
PE20130346A1 (es) Compuestos heterociclicos fusionados
MD20140084A2 (en) New indolizine derivatives, method for preparing same and pharmaceutical compositions containing same
PE20120834A1 (es) Derivados de furopirimidindiona como moduladores de trpa1
PE20061442A1 (es) Heterociclicos como agonistas del receptor de acido nicotinico para el tratamiento de dislipidemia
HRP20191268T1 (hr) Derivati tieno[2,3-c]pirol-4-ona kao inhibitori erk
PE20090492A1 (es) Compuestos heterociclos como inhibidores de cinasa de fosfatidil-inositol-3
AR078536A1 (es) Derivados de pirazol como ligandos del receptor de estrogeno
PE20130279A1 (es) Compuestos heteroarilo nitrogenados
PE20090049A1 (es) Derivados de piridopirimidina como moduladores de la actividad de pde 4

Legal Events

Date Code Title Description
FD Application declared void or lapsed